Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand.
Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together with an expansion of the study design.
BTX 1702 is a new formulation which leverages our proprietary drug delivery system Permetrex™ with synthetic cannabidiol.
Our BTX 1702 product offers a novel potential treatment for papulopustular rosacea, with a unique mechanism of action, which could target several aspects in the pathogenesis of the disease.
We are very excited to be initiating this clinical study with leading investigators in Australia and New Zealand.
[The person featured in the above image is not an affiliate or actual patient of Botanix Pharmaceuticals Ltd.]